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ABSTRACT
Treatment non-adherence is a complex problem
encountered in all therapy areas, particularly in
chronic diseases such as psoriasis vulgaris. To
address adherence issues, focus is turning
towards developing interventions tailored to
individual patient needs. Topical therapies
remain the mainstay of psoriasis treatment;
however, these are associated with additional
challenges where preparations may be perceived
as messy, inconvenient and time-consuming.
Once-daily fixed-combination calcipotriene
0.005% (Cal) and betamethasone dipropionate
0.064% (BD) topical suspension is a convenient
and effective first-line topical psoriasis therapy.
To improve the patient experience with this
treatment, we undertook a program—in
collaboration with patients and healthcare
professionals—to develop a topical treatment
delivery system that further caters to the unmet
needs of psoriasis patients. The finalized
Applicator comprises: an easy to operate
pump-action lever providing consistently
accurate dose delivery (0.05 g of Cal/BD topical
suspension/pump); a single-tip nozzle allowing
for targeted, precise application to body and
scalp psoriasis plaques; two spreading surfaces
designed to disperse treatment evenly across
both large and small affected skin areas; and a
protective cover. Patients listed the following as
key Applicator attributes: ease of use, ‘less messy’
treatment, precise application, consistent
accurate dosing, ‘no touch’ treatment,
reduction of wasted treatment and extended
length of reach for awkward areas. Although
these attributes were well received by most
patients and healthcare professionals, some
patients did not perceive them all as
improvements over their current treatment;
this highlights the need to tailor treatment for
each individual patient’s requirements. For
patients who prefer using the Applicator, it has
thepotential to provide greater control over their
daily psoriasis management by providing a
simple, convenient treatment option, with
minimal impact on their lives. The Applicator
may represent a more acceptable treatment
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INTRODUCTION
Poor adherence to treatment in chronic diseases
is a universal challenge of striking magnitude;
the World Health Organization (WHO) has
calculated that adherence to long-term
treatment for chronic illnesses in developed
countries averages only 50%, providing
undeniable evidence that many patients
experience difficulty in following treatment
recommendations [1]. Irrespective of the route
of administration, a drug that has demonstrated
high efficacy in the acute-phase
‘compliance-friendly’ environment of a clinical
trial may still be a therapeutic failure in the
real-world setting if not accepted by the patient
[2]. The reasons behind this failure can be
complex and influenced by the individual
patient’s acceptability of the treatment [2, 3].
What is evident is a greater need for a
patient-centric approach to tackle poor
adherence and the WHO recognizes that
interventions must be tailored to the particular
illness-related demands experienced by the
patient [1].
Psoriasis vulgaris is one such chronic disease
that, while generally not life threatening, has no
cure and can have a profound impact on a
patient’s physical, psychological and social
well-being [4]. It is an inflammatory skin
disorder that affects between 2% and 4% of
Western populations [5] and is recognized by
the WHO as a painful and debilitating disease
[6]. More than 80% of patients are able to
manage their psoriasis with topical treatments
alone [7]; however, adherence to topical
treatments is poor, with one-third of
prescriptions never being filled and between
39% and 73% of patients not using their
medication as directed [8]. Poor adherence to
topical therapy is exacerbated by the necessity of
application, which can be cumbersome, messy
and time-consuming [8, 9]. The fixed
combination of calcipotriene 0.005% (Cal) and
betamethasone dipropionate 0.064% (BD) as a
topical suspension (Taclonex topical
suspension/Daivobet gel) is a first-line topical
therapy for the once-daily treatment of all
severities of psoriasis vulgaris of the scalp and
body (US label), and mild-to-moderate psoriasis
vulgaris of the body and all severities of psoriasis
vulgaris of the scalp (EU label), in adults [10].
This topical suspension was developed to offer
minimal impact on the patient’s daily routine
and thereby promote patient adherence [11–13].
Compared with other chronic therapy areas
where drug delivery systems have been
developed to assist patients in the
self-management of their disease [14, 15],
innovation in topical psoriasis treatment
delivery systems is rare. We, therefore,
undertook a program of market research and
device design, in collaboration with psoriasis
patients and healthcare professionals (HCPs,
includes general practitioners, nurses and
dermatologists), to develop a patient-friendly
delivery system for Cal/BD topical suspension,
which improves the treatment and application
experience by meeting the needs of its
end-users. In this way, we aimed to produce
an Applicator that was tailored to the needs of
the psoriasis patient, thereby favoring improved
treatment adherence.
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UNDERSTANDING THE BURDEN
OF PSORIASIS
Our initial step was to gain insights into the
current issues that psoriasis patients encounter,
so as to be better informed about their unmet
needs. In June 2010, an initial ethnographic
pilot study was performed in a small cohort of
patients with psoriasis vulgaris [16]. Patients
were studied for 1 (n = 42) or 2 days (n = 14),
using a combination of interview, observation,
longitudinal analysis and photo diaries. This
qualitative study guided the development of a
68-part online questionnaire (completed
between December 2010 and January 2011) to
enable quantification of the burden of psoriasis;
this online survey was endorsed by HCPs [16].
Psoriasis Patients Carry a Substantial
Burden of Disease
Most patients (60%) who completed the online
questionnaire reported that psoriasis had a high
impact on their daily life [16]. Physical
symptoms reported by patients included pain,
bleeding and most commonly itch. Itch is a
distressing aspect of psoriasis [17], which can
cause pronounced discomfort, is often
associated with loss of sleep and can
negatively impact daily activities [18]. Indeed,
54% of those patients experiencing itch also
reported problems sleeping [16].
The role psychological issues play in the
burden associated with psoriasis cannot be
underestimated—emotional stress related to
their appearance, as well as the feeling of
stigmatization, is highly prevalent among
patients. A quarter (27%) of patients
completing the survey agreed ‘‘my psoriasis
dictates how I lead my life’’ [16]. Patients
reported worrying about their psoriasis, that
they try to hide their psoriasis and are very
worried that other people perceive them as
dirty. Furthermore, patients often feel dirty and
constantly check their appearance. A feeling of
hopelessness is also common to psoriasis
patients, with 48% believing that nothing can
be done about their disease [16].
Topical Psoriasis Treatment is a Significant
Burden in Itself
In addition to the burden of disease, there is a
considerable burden associated with psoriasis
treatment, which is heightened by the chronic
nature of the disease and thus the need to treat
over the long term. Of those patients who
completed the survey, most (92%) were
prescribed a topical treatment and less than
half (46%) indicated that they did not fully
adhere to their treatment [16]. Reasons given
for non-adherence included deviation from the
prescribed regimen (only applying treatment
when they thought it necessary; forgetting to
apply it), as well as unacceptability of the
treatment vehicle and its lack of convenience
[16].
A further ethnographic study with both
patients (n = 18) and HCPs (n = 19) was
performed in 2010 to gain insight into the
treatment journey and to explore the needs of
individual patients (data on file, LEO Pharma).
Participants contributed through 30-min
telephone interviews (all patients and HCPs),
3-h in-depth interviews at home (n = 18
patients) and/or a 1-week diary study (n = 15
patients). All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
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This study identified a number of additional
challenges that psoriasis patients may face.
These included a lack of control over
treatment and inconsistent dosing (in contrast
to other forms of medication, such as tablets, an
exact daily dose of topical treatment is very
difficult to manage), difficulty getting treatment
out of the container (particularly patients with
psoriatic arthritis), too much wastage of
treatment and inability to reach awkward
areas. In addition, this study aimed to
generate ideas for a delivery system that
patients felt would aid their treatment routine.
Patients were shown a variety of off-the-shelf
cosmetic and domestic products and provided
feedback on whether the design of these
products would be helpful in treating their
psoriasis, including any modifications they
could conceive may improve treatment. While
patients held differing views, some design
features were identified that could potentially
benefit psoriasis patients, regardless of their
disease status. These features related to
handling (‘mess-free’ hands, easy to hold and
the ability to reach awkward areas), application
(intuitive and easy to use, precise application
and reduced wastage) and packaging (easy to
clean, estimation of remaining treatment and a
modern visual appeal).
By adopting insights directly from psoriasis
patients on the burden of psoriasis and its
treatment, the aim was to develop a
patient-friendly delivery system that addressed
some of their previously unmet needs as
detailed above; a key goal of this process was
to improve their treatment experience. To
maximize the potential of the delivery system,
creative input and feedback were sought from
both patients and HCPs throughout the
development program to understand their
preferences for every aspect of design.
A COLLABORATIVE APPROACH
TO DESIGNING THE CAL/BD
TOPICAL SUSPENSION APPLICATOR
Our objective was to provide a robust delivery
system that could both dispense and disperse
Cal/BD topical suspension. To combine the
patient-identified features together with
technical capabilities, an applicator device was
considered to be the most appropriate system,
comprising a cartridge containing the topical
suspension and a separate applicator head that
was attached at the start of the treatment by the
user.
Initially, the intention was to develop two
different Applicators designed to specifically
target psoriasis of the scalp or of the body.
However, with insights gained from continuous
testing of prototype applicators with patients
and HCPs, the Applicator evolved into a single
delivery system suitable for both body and scalp
psoriasis. Applicator prototypes were developed
with a range of features (Table 1). Over a 2-year
period (2011–2013), the prototypes were
assessed and modified through an iterative
series of qualitative, quantitative and usability
studies (Fig. 1), whereby patients (n = 12–60)
and HCPs (n = 2–79) were given the
opportunity to provide feedback, suggest
modifications and actively contribute towards
optimizing the design of the Applicator during
each assessment phase (data on file, LEO
Pharma).
Overall, the concept was received as a
modern and innovative approach to topical
psoriasis treatment application. The Applicator
prototypes were perceived to be portable,
robust, intuitive to handle and use and easy to
store. In terms of treatment experience, patients
rated the key features to be: ease of use, a ‘less
messy’ treatment approach, precision
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application, consistent accurate dosing, ‘no
touch’ treatment, reduction of wasted
treatment, and extended length of reach for
awkward areas. The nozzle feature allows
precision dispensing direct to the psoriasis
plaque, thereby reducing contact with
unaffected skin. The ‘no touch’ design negates
the need to disperse the treatment with hands
and/or fingers; instead, the in-built spreading
surfaces can be used to perform this task.
Feedback from patients indicated that a
single-tip Applicator offered the widest appeal
to those with scalp psoriasis by meeting certain
application needs of these patients: ease of use,
consistent accurate dosing, a ‘less messy’
treatment approach, and a reduction of wasted
treatment. The single-tip nozzle was also seen to
be most suitable for application to smaller body
areas, such as the knuckles, whereas the large
spreading surface would be able to cover large
body surface areas quickly. This highlighted a
significant advantage of combining both of
these features into a single Applicator to create
one device for both scalp and body. Two further
key modifications suggested by patients were to
provide an indication of the amount of topical
suspension dispensed and the amount of
medication remaining in the Applicator. In
response to these recommendations, the
amount of Cal/BD topical suspension
dispensed was included within the Applicator
packaging and the Applicator plunger was made
visible from the underside of the cartridge so
the user is able to estimate the remaining
volume of Cal/BD topical suspension and
assess when the cartridge is empty.
The key concern that patients and HCPs had
with the Applicator was associated with hygiene
Table 1 Steps taken during the design process to reﬁne each individual feature of the calcipotriene 0.005% and
betamethasone dipropionate 0.064% topical suspension Applicator
Feature Applicator development steps
Topical suspension Applicator
(for scalp application)
Topical suspension Applicator (for body
and scalp application)
Spreadability Amount of nozzles for optimal spreading
Length of nozzles for best targeting of the scalp
Shape of Applicator spreading surface
Materials of spreading surface
Hygiene of spreading surface
Ergonomics Cartridge diameter (grip size)
Cartridge and Applicator length for optimal handling
Cartridge diameter (grip size)
Cartridge and Applicator length for optimal
handling
Angle Angle of nozzle(s) for optimal scalp and hairline
application
Angle of lever and spreading surface for optimal
scalp and body application
Nozzle Number of nozzles (one versus three)
Sensitivity (soft versus hard nozzles)
One nozzle for precise application
Larger spreading plate for larger plaques
Delivery Lever versus dial mechanism
Placement of lever on Applicator
Consistent dosing
Placement of lever on Applicator
Cover Cover for protecting nozzles Cover for leakage prevention
Design for cleanliness and ease of use
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and wanting reassurance that cleaning the
device would be effective. Microbiological
testing was performed to allay these concerns.
Two studies assessed the potential for
contamination of the Applicator nozzle and
spreading surfaces (data on file, LEO Pharma).
The first study demonstrated that the
recommended cleaning procedure (wiping the
Applicator head with a clean, dry tissue)
effectively removes an acceptable level of viable
microorganisms. The second study
demonstrated that although microorganisms
may be transferred from the patient’s skin to
the Applicator, no contamination of the Cal/BD
topical suspension in the cartridge was observed.
VALIDATION OF THE FINAL DESIGN
OF THE TOPICAL SUSPENSION
APPLICATOR
The Applicator consists of a cartridge
containing Cal/BD topical suspension and an
Applicator head with a separate protective cover
(Fig. 2). The Applicator has a pump-action lever
that is easy to operate and provides consistently
accurate dose delivery (0.05 g of Cal/BD topical
Fig. 1 Research studies undertaken to guide the design of
the Cal/BD topical suspension Applicator. Light gray
indicates studies evaluating opinion and preference; dark
gray indicates studies evaluating usability; participants were
not shown the actual prototypes until patent applications
had been ﬁled on the device; Cal/BD calcipotriene 0.005%
and betamethasone dipropionate 0.064%, HCPs healthcare
practitioners (includes general practitioners, nurses and
dermatologists)
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suspension/pump); a single-tip nozzle allows for
targeted and precise application to psoriasis
plaques; and two spreading surfaces designed
to disperse Cal/BD gel evenly across both large
and small areas of affected skin.
In 2013, the production version of the
Applicator, including its labeling and
packaging, was subject to assessment in a
multi-part human factor study (Fig. 1; data
on file, LEO Pharma). The study was
performed in a simulated-use (home-like)
environment at two study centers in the US.
Study participants were patients (n = 21–45)
and carers (n = 9–15) who would be end-users
of the Applicator. Patients were provided
with an Applicator to apply non-medicated
topical suspension vehicle to their own body,
while carers applied the non-medicated
topical suspension vehicle to a mannequin.
The first part of the study focused on
validating the Applicator’s instructions for
use; all users were prompted to consult the
instructions, which led to all being able to
correctly and safely assemble and use the
Applicator. The second part of the study
validated the design of the production
version of the Applicator, as provided in its
packaging. During this part of the study,
participants were allowed to proceed with
assembling and using the Applicator
uninterrupted to ensure a scenario as close
to ‘real life’ as possible. All patients and
carers were able to use the Applicator
correctly and safely to either self-apply or
assist with application of topical suspension
vehicle; indeed participants in both parts of
the study rated the Applicator above average
for ease of use (Fig. 3), requiring little
assistance from the instructions for use to
successfully assemble and apply placebo
topical suspension vehicle. Notably, all
patients with physician-diagnosed arthritis
in their hands (n = 10) were able to grip the
Applicator and dispense Cal/BD topical
suspension without difficulty. The human
factor validation analysis additionally
concluded there were no unacceptable risks
associated with use of the Applicator.
Fig. 2 Calcipotriene 0.005% and betamethasone dipropi-
onate 0.064% topical suspension Applicator (a) and its
component parts (b)
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EVALUATING THE FINAL DESIGN
OF THE TOPICAL SUSPENSION
APPLICATOR
The concluding phase of development was
evaluation of the Applicator by existing users
(n= 18) and prescribers (n= 14) of Cal/BD
topical suspension (Fig. 1). Two streams of
qualitative individual interviews were performed
to explore patient response and acceptability and
physician perspectives on the device. Patient
response was positive with 89% indicating they
preferred the Applicator to the existing
presentation of Cal/BD topical suspension in a
bottle; their preference was primarily based on the
Applicator offering consistent and controlled
dosing and precise delivery of treatment to target
areas (data on file, LEO Pharma). Other positive
responses included an enhanced ability to reach
‘hard-to-reach’ or ‘hard-to-see’ areas and better
control over dosing for scalp application.
Approximately, one-quarter of the patients (28%)
indicated the ‘no touch’ feature was a major
attribute of the Applicator. Most of the surveyed
physicians also recognized the samebenefits of the
Applicator as highlighted by the patients,
although it was clear that these benefits appealed
more to patients than physicians. Furthermore,
only one physician, who had personal experience
of a skin condition, spontaneously identified the
‘no touch’ option as a benefit.
WHAT DOES THE APPLICATOR
DELIVERY SYSTEM OFFER
PATIENTS?
The value of the Applicator design is firmly
based on the insights gained from the patients
during the development process; having
handled and used the Applicator prototypes,
patients were able to identify issues that were
previously not fully appreciated. In so doing, we
believe the Applicator has the potential to be a
key step toward bridging the gap in topical
psoriasis treatment, offering features that
address a number of unmet patient needs. Key
attributes of the Applicator are discussed below.
Consistently Accurate Dosing
and Precision Application
Dosing of psoriasis topical treatments has
historically relied on a relatively inaccurate
and subjective tool for measurement—the
Fig. 3 Average user rating (scale 1–7) of the calcipotriene
0.005% and betamethasone dipropionate 0.064% topical
suspension Applicator in the human factors study to
validate the instructions for use (part 1) and to validate the
ﬁnal Applicator design as provided in its packaging (part 2)
(a) and a breakdown of the individual user scores (b)
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‘fingertip unit’ (FTU). This is defined as the
amount of topical treatment expressed from a
5-mm-diameter nozzle and applied from the
distal skin crease to the tip of the index finger of
an adult; two FTUs approximately equate to 1 g
of topical treatment [7]. Concern arises with
patients because they are not prescribed an
exact daily dose, which leads to the perception
that they have poor control over the day-to-day
management of their psoriasis, both with over-
and with under-treatment. With the
consistently accurate dosing feature of the
Applicator (0.05 g of topical suspension/
pump), patients will be able to accurately
monitor and tailor the amount of topical
suspension they are using each day, which
should allow them to feel more reassured in
managing the amount of treatment product
that they are applying to their skin, avoiding
ambiguities and allaying worries about the dose
level. Additionally, the consistently accurate
dosing feature may enable HCPs to provide
guidance and recommendations to patients
regarding topical treatment dose.
The nozzle and small spreading area allow
precise and targeted application of treatment,
which will minimize exposure of healthy,
unaffected skin to treatment. This has the
potential to be especially useful for those
patients with only small areas of affected skin,
as well as those needing to treat their scalp,
providing a greater level of control in their daily
treatment regimen.
‘No Touch’ Treatment
During the development of this Applicator, it
became apparent from patient feedback that
there is a clear distinction between those who
want or need to have physical contact with
their plaques and those who do not want to
touch them. With the ‘no touch’ feature, the
Applicator allows the latter subgroup of patients
to apply treatment to affected areas without the
need for physical contact. This feature may be
an important consideration when treatment is
applied by a third party/caregiver—patients
may feel less self-conscious if the carer does
not have direct contact with their plaques, and
it will also reduce the carer’s contact with the
topical suspension, decreasing their exposure to
the active ingredients. This feature of the
Applicator also makes it possible for patients
and carers to apply the treatment without
getting greasy hands and removes the
necessity to wash hands after use, thus
reducing the number of treatment steps.
Neater and Less Messy
Current topical treatments are largely available
in tubes and bottles, which according to patient
feedback may crack and leak, meaning patients
need to take extra care in storing and
transporting these products. The Applicator
has been designed to be a robust delivery
system that does not break, with a protective
cover to prevent accidental delivery or leakage.
These features may be of particular importance
to patients because of the potential for
increased convenience and reduced disruption
of their daily routine.
Improved Convenience
The Applicator offers various attributes
designed to appeal to a diverse range of
psoriasis patients by providing simple
solutions to overcome some of their previous
unmet needs. In doing so, a reduction in
treatment burden would be expected, resulting
in greater convenience to these patients. In
addition, for those who currently have to rely
on assistance with treatment application, the
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Applicator has the potential to offer increased
independence, which can further allow the
patient a greater feeling of control.
The Applicator is easy to use; it is
ergonomically shaped to be held comfortably
in the hand, and it is easy to dispense and apply
treatment directly to psoriasis plaques. This
feature should be of particular benefit to those
patients who are less dextrous, such as those
with psoriatic arthritis, who struggle to open
tubes and bottles. The Applicator also provides
patients with extended reach for direct and
targeted application to some hard-to-reach/
hard-to-see areas, both on the body and on
the scalp. As an example, for those who lack the
flexibility to reach their lower legs and feet, the
extended reach of the Applicator may be able to
aid treatment application without the need to
rely on a carer.
ONE SIZE DOES NOT FIT ALL
Overall, the Applicator was very well received
by most patients and HCPs who participated in
its development and final assessment. The
research demonstrated that patients identified
many different attributes of the topical
suspension Applicator address some of their
unmet needs. However, it was apparent that
some patients do not recognize the attributes of
the Applicator as beneficial to themselves and
remain loyal to their current treatment. These
observations indicate that resolving treatment
adherence is not a simple matter—patients are
individuals who have different experiences and
expectations of topical treatments and see value
in different aspects of treatment. Given the
most common treatment-related reasons for
non-adherence include treatment
inconvenience (23%) and the treatment being
too messy (16%), the attributes of the
Applicator described herein may have the
potential to improve adherence. However,
certain attributes of the Applicator are likely to
be met more favorably than others within
particular patient types, such as the ‘no touch’
feature, which appealed to those not wishing to
touch their plaques but not to those needing
physical contact with their skin as an essential
part of therapy. The studies described here
highlight the importance of tailoring
treatment to the needs of each patient [1].
CONCLUSION
The Cal/BD topical suspension Applicator is an
innovative delivery system within the psoriasis
therapy area. The foundations of its innovation
are in the collaborative approach adopted in its
development, gaining insight from patients and
HCPs throughout the process and resulting in a
drug delivery system with a range of attributes,
addressing a number of unmet needs as
communicated by patients with psoriasis.
However, the Applicator will not be every
patient’s preferred choice, and each patient
should have their own treatment tailored to
their requirements. For those who do gain
benefit from the Applicator, it has the
potential to allow them greater control over
the self-management of their psoriasis by
providing a more simple and convenient
treatment option that has minimal impact on
their lives. In so doing, the Applicator may
become the treatment of choice for some
patients; in those patients, the Applicator may
promote treatment adherence over the long
term as a more acceptable therapy option.
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